Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.

S. De Placido, C. Gallo, M. De Laurentiis , G. Bisagni, G. Arpino, MG. Sarobba, F. Riccardi, A. Russo, L. Del Mastro, AA. Cogoni, F. Cognetti, S. Gori, J. Foglietta, A. Frassoldati, D. Amoroso, L. Laudadio, L. Moscetti, F. Montemurro, C. Verusio, Antonio BernardoV. Lorusso, A. Gravina, G. Moretti, R. Lauria, A. Lai, C. Mocerino, S. Rizzo, F. Nuzzo, P. Carlini, F. Perrone

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)474-485
Number of pages9
JournalThe Lancet Oncology
Publication statusPublished - 2018

Cite this